A phase 2 study found that riluzole slowed brain metabolic decline and improved cognitive performance in patients with mild Alzheimer's disease. The drug targets glutamate dysregulation thought to contribute to the development of Alzheimer's.
The Alzheimer's Drug Discovery Foundation and The Association for Frontotemporal Degeneration recommend adopting best practices in designing exploratory trials, including rigorous statistical analyses and biomarker selection. These recommendations aim to reduce costs and improve patient engagement in clinical trials.
A global research consortium is proposed to collect and share digital speech and language data to detect early signs of Alzheimer's. The consortium aims to create a comprehensive, harmonized repository of samples from diverse cohorts to develop biomarkers that can monitor disease progression.
A study supported by the Alzheimer's Drug Discovery Foundation found that rotigotine, a dopamine-acting drug, improved frontal lobe executive function and daily activities in patients with mild-to-moderate Alzheimer's disease. The treatment also enhanced dopaminergic pathways reaching this section of the brain.
Eugenia Trushina, Ph.D., Mayo Clinic Rochester researcher, receives $600,000 to develop new drug candidates restoring mitochondrial function in treating Alzheimer's. The ADDF-Harrington partnership aims to accelerate discovery into clinical studies for a potential cure.
A comprehensive review highlights novel approaches to slow or prevent Alzheimer's disease, focusing on the effects of aging on the brain. Combination therapy is deemed necessary for better treatment outcomes, similar to other major diseases.